pyrazines has been researched along with Neutropenia in 39 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (15.38) | 18.2507 |
| 2000's | 10 (25.64) | 29.6817 |
| 2010's | 21 (53.85) | 24.3611 |
| 2020's | 2 (5.13) | 2.80 |
| Authors | Studies |
|---|---|
| Aurran-Schleinitz, T; Chen, DY; Cheson, BD; D'Sa, S; Forconi, F; Frigault, MM; Furman, RR; Greenwald, D; Hamdy, A; Iyengar, S; Izumi, R; Kastritis, E; Kersten, MJ; Kothari, J; Lee, SK; McCarthy, H; Minnema, MC; Mittag, D; Owen, RG; Patel, P; Rule, S; Thomas, SK; Tournilhac, O; Walter, H; Wei, H; Zinzani, PL | 1 |
| Cash, T; Fox, E; Liu, X; Minard, CG; Reid, JM; Scheck, AC; Weigel, BJ; Wetmore, C | 1 |
| Bunworasate, U; Caguioa, PB; Choi, CW; Chung, JS; Comia, NS; Do, YR; Jootar, S; Jung, CW; Kim, DW; Kim, DY; Kim, H; Kim, HJ; Kim, JA; Kim, SH; Kong, JH; Kwak, JY; Lee, SE; Lee, WS; Mun, YC; Oh, SJ; Park, J; Park, JS; Reksodiputro, AH; Shin, HJ; Zang, DY | 1 |
| Eatock, MM; Gallagher, R; James, CR; Law, D; Millar, J; Morris, M; Napier, E; Purcell, C; Turkington, RC; Wilson, RH | 1 |
| Gupta, K; Klimenkova, O; Klimiankou, M; Kuznetsova, I; Meyer, J; Moore, MA; Skokowa, J; Welte, K; Zeidler, C | 1 |
| Anderson, KC; Bahlis, N; Baz, R; Belch, A; Chen, C; Chen, M; Hofmeister, CC; Jacques, C; Jagannath, S; Jakubowiak, A; Lacy, M; Lentzsch, S; Lonial, S; Matous, J; Mikhael, J; Raje, N; Richardson, PG; Shustik, C; Siegel, DS; Song, K; Vesole, D; Vij, R; Yu, Z; Zaki, MH | 1 |
| Benevolo, G; Boccadoro, M; Bringhen, S; Cavo, M; Di Raimondo, F; Falcone, AP; Franceschini, L; Gaidano, G; Gottardi, D; Grasso, M; Guglielmelli, T; Larocca, A; Levi, A; Magarotto, V; Marasca, R; Mina, R; Montefusco, V; Morabito, F; Musto, P; Nozzoli, C; Offidani, M; Omedé, P; Palumbo, A; Passera, R; Patriarca, F; Petrucci, MT; Ria, R; Rossi, D; Vincelli, ID; Zambello, R | 1 |
| Ashcroft, AJ; Bird, JM; Brown, JM; Cairns, DA; Cavenagh, J; Cavet, J; Chalmers, A; Cook, G; Drayson, MT; Fletcher, M; Hunter, H; Morris, TC; O'Connor, S; Parrish, C; Snowden, JA; Williams, C; Yong, K | 1 |
| Curtis, BR; Davies, SM; Filipovich, AH; Grimley, MS; Jodele, S; Jordan, MB; Khandelwal, P; Marsh, R | 1 |
| Cheng, J; Lamy, T; Loughran, TP; Malysz, J; Ochmann, M; Talamo, G | 1 |
| Fu, W; Hou, J; Huang, H; Peng, L; Zhang, C; Zhou, L | 1 |
| Bátorová, A; Mistrík, M; Roziaková, L | 1 |
| Becerra, C; Bence Lin, A; Braiteh, F; Calvo, E; Galsky, MD; Hurt, K; Hynes, SM; Jameson, G; Lin, J; McKane, S; McWilliams, R; Richards, D; Von Hoff, D; Wickremsinhe, ER | 1 |
| Chow, L; Eckhardt, SG; Gore, L; Lieu, C; Morrow, M; O'Bryant, CL; Pierson, AS; Tran, ZV; Wright, JJ | 1 |
| Bahlis, NJ; Barr, PM; Cooper, BW; Dowlati, A; Fu, P; Gerson, SL; Horvath, N; Koc, ON; Lazarus, HM; Snell, MR | 1 |
| Biesma, B; Bosquée, L; Chan, KC; De Marinis, F; Gans, S; Germonpré, P; Gervais, R; Lee, JS; Makhson, A; Manikhas, G; Morgan, B; Park, K; Planchard, D; Ramlau, R; Reck, M; Scagliotti, GV; Szczesna, A; Vansteenkiste, J; von Pawel, J; Zhu, Y | 1 |
| Bekaii-Saab, T; Byrd, JC; Culler, K; Grever, MR; Lesinski, GB; Lucas, DM; Ramaswamy, B; Ruppert, AS; Schaaf, LJ; Shapiro, CL; Wilkins, D; Wright, JJ; Young, DC | 1 |
| Chen, C; Eckhardt, SG; Pugh, TJ; Raben, D; Rabinovitch, R; Rusthoven, KE; Swing, R | 1 |
| Alimena, G; Breccia, M; Cilloni, D; D'Auria, F; Gottardi, E; Latagliata, R; Mandelli, F; Musto, P; Saglio, G; Sanpaolo, G | 1 |
| Khan, ML; Stewart, AK | 1 |
| Balleisen, S; Bruns, I; Fenk, R; Haas, R; Kobbe, G; Kondakci, M; Liese, V; Neubauer, F; Saure, C; Schröder, T | 1 |
| Abonour, R; Anderson, KC; Bengoudifa, BR; Bourquelot, PM; de Magalhaes-Silverman, M; Goldschmidt, H; Hazell, K; Lonial, S; Matous, J; Siegel, D; Vij, R; Wolf, JL | 1 |
| Bo, J; Gao, C; Huang, W; Kang, W; Li, H; Li, J; Yu, L; Zhao, Y; Zhou, D | 1 |
| Chen, C; Jimenez-Zepeda, VH; Kukreti, V; Reece, DE; Tiedemann, R; Trudel, S | 1 |
| Cilley, J; Evens, AM; Gallot, L; Gordon, LI; Larson, A; Patton, D; Rademaker, A; Roy, R; Spies, S; Variakojis, D; Winter, JN | 1 |
| Bertolet, BD | 1 |
| Colson, K; Doss, DS; Swift, R; Tariman, J; Thomas, TE | 1 |
| Adams, J; Berenson, JR; Jarutirasarn, SG; Lee, SP; Mapes, R; Morrison, B; Purner, M; Sadler, K; Schenkein, D; Swift, R; Vescio, RA; Wilson, J; Yang, HH | 1 |
| Anderson, KC; Ben-Yehuda, D; Cavenagh, JD; Facon, T; Harousseau, JL; Irwin, D; Lonial, S; Richardson, PG; San Miguel, JF; Schuster, MW; Sonneveld, P; Stadtmauer, EA | 1 |
| Bold, R; Davies, AM; Gandara, DR; Gumerlock, PH; Lara, PN; Lau, DH; Lenz, HJ; Ruel, C; Schenkein, DP; Shibata, S | 1 |
| Albanell, J; Awada, A; Baselga, J; Canney, PA; Cardoso, F; Dirix, LY; Gascon, P; Gil, T; Piccart, MJ | 1 |
| Berenson, JR; Hilger, J; Lee, SP; Mapes, R; Morrison, B; Nassir, Y; Swift, R; Vescio, RA; Wilson, J; Yang, HH; Yellin, O | 1 |
| Bertolet, BD; Pepine, CJ; White, BG | 1 |
| Matsumori, A; Sasayama, S; Sato, Y | 1 |
| Marsh, JD; Vander Heide, RS | 1 |
| Benson, L; Einzig, AI; Grove, WR; Lathia, CD; Roca, J; Sklarin, NT; Thomas, S; Wiernik, PH | 1 |
| Benjamin, RS; Burgess, MA; Gray, R; Jenkins, J; Papadopolous, NE; Patel, SR; Plager, C; Sidhu, G | 1 |
| Bowling, MK; Donehower, RC; Grochow, LB; Long, GS; Noe, DA; Rowinsky, EK; Sartorius, SE | 1 |
| Drengler, RL; Eckhardt, SG; Felton, SA; Garner, AM; Hammond, LA; Hidalgo, M; Mallikaarjun, S; Patnaik, A; Rowinsky, EK; Siu, LL; Tammara, BK; Von Hoff, DD | 1 |
4 review(s) available for pyrazines and Neutropenia
| Article | Year |
|---|---|
Bortezomib-thalidomide-based regimens improved clinical outcomes without increasing toxicity as induction treatment for untreated multiple myeloma: a meta-analysis of phase III randomized controlled trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase III as Topic; Drug-Related Side Effects and Adverse Reactions; Humans; Induction Chemotherapy; Multiple Myeloma; Neoadjuvant Therapy; Neutropenia; Peripheral Nervous System Diseases; Pyrazines; Randomized Controlled Trials as Topic; Survival Analysis; Thalidomide; Treatment Outcome | 2014 |
[Pomalidomide in the treatment of relapsed and refractory multiple myeloma].
Topics: Administration, Oral; Boronic Acids; Bortezomib; Dexamethasone; Disease-Free Survival; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Neutropenia; Pyrazines; Thalidomide | 2014 |
Precautions for use and adverse effects of vesnarinone: potential mechanisms and future therapies.
Topics: Animals; Clinical Trials as Topic; Death, Sudden; Heart Failure; Humans; Monitoring, Physiologic; Multicenter Studies as Topic; Neutropenia; Pyrazines; Quinolines; Quinolones | 2004 |
Bortezomib, a newly approved proteasome inhibitor for the treatment of multiple myeloma: nursing implications.
Topics: Anemia; Antineoplastic Agents; Asthenia; Boronic Acids; Bortezomib; Clinical Trials as Topic; Drug Approval; Drug Monitoring; Gastrointestinal Diseases; Humans; Hypotension; Multiple Myeloma; Neutropenia; Nurse's Role; Oncology Nursing; Patient Care Planning; Patient Education as Topic; Peripheral Nervous System Diseases; Protease Inhibitors; Pyrazines; Quality of Life; Thrombocytopenia; Water-Electrolyte Imbalance | 2004 |
29 trial(s) available for pyrazines and Neutropenia
| Article | Year |
|---|---|
Acalabrutinib monotherapy in patients with Waldenström macroglobulinemia: a single-arm, multicentre, phase 2 study.
Topics: Agammaglobulinaemia Tyrosine Kinase; Aged; Antineoplastic Agents; Benzamides; Female; Gastrointestinal Diseases; Humans; Male; Middle Aged; Molecular Targeted Therapy; Myeloid Differentiation Factor 88; Neoplasm Proteins; Neutropenia; Pain; Protein Kinase Inhibitors; Pyrazines; Quality of Life; Recurrence; Respiratory Tract Infections; Salvage Therapy; Treatment Outcome; Waldenstrom Macroglobulinemia | 2020 |
A phase 1 study of prexasertib (LY2606368), a CHK1/2 inhibitor, in pediatric patients with recurrent or refractory solid tumors, including CNS tumors: A report from the Children's Oncology Group Pediatric Early Phase Clinical Trials Network (ADVL1515).
Topics: Adolescent; Central Nervous System Neoplasms; Checkpoint Kinase 1; Checkpoint Kinase 2; Child; Child, Preschool; Female; Humans; Leukopenia; Male; Maximum Tolerated Dose; Neoplasm Recurrence, Local; Neoplasms; Neutropenia; Protein Kinase Inhibitors; Pyrazines; Pyrazoles; Thrombocytopenia; Young Adult | 2021 |
Phase III Clinical Trial (RERISE study) Results of Efficacy and Safety of Radotinib Compared with Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia.
Topics: Adult; Benzamides; Drug Administration Schedule; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Neutropenia; Protein Kinase Inhibitors; Pyrazines; Remission Induction; Thrombocytopenia; Treatment Outcome | 2017 |
A phase I trial of bortezomib in combination with epirubicin, carboplatin and capecitabine (ECarboX) in advanced oesophagogastric adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carboplatin; Deoxycytidine; Epirubicin; Female; Gastrointestinal Neoplasms; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Proteasome Inhibitors; Pyrazines | 2014 |
Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Immunologic Factors; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Neutropenia; Pyrazines; Thalidomide; Treatment Outcome | 2014 |
Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Survival; Female; Follow-Up Studies; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Maintenance Chemotherapy; Male; Melphalan; Middle Aged; Multiple Myeloma; Neutropenia; Peripheral Nervous System Diseases; Prednisone; Pyrazines; Thalidomide; Thrombocytopenia; Treatment Outcome | 2014 |
High-dose chemotherapy plus autologous stem-cell transplantation as consolidation therapy in patients with relapsed multiple myeloma after previous autologous stem-cell transplantation (NCRI Myeloma X Relapse [Intensive trial]): a randomised, open-label,
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Consolidation Chemotherapy; Cyclophosphamide; Dexamethasone; Disease Progression; Doxorubicin; Female; Humans; Induction Chemotherapy; Intention to Treat Analysis; Male; Melphalan; Middle Aged; Multiple Myeloma; Neutropenia; Peripheral Nervous System Diseases; Proportional Hazards Models; Pyrazines; Recurrence; Retreatment; Salvage Therapy; Stem Cell Transplantation; Thrombocytopenia; Time Factors; Transplantation, Autologous | 2014 |
Bortezomib for refractory autoimmunity in pediatrics.
Topics: Adolescent; Adult; Anemia, Hemolytic, Autoimmune; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Autoimmunity; Boronic Acids; Bortezomib; Child; Child, Preschool; Drug Administration Schedule; Female; Humans; Infant; Male; Neutropenia; Plasma Cells; Plasmapheresis; Proteasome Inhibitors; Pyrazines; Retrospective Studies; Rituximab; Thrombocytopenia | 2014 |
Phase I Study of CHK1 Inhibitor LY2603618 in Combination with Gemcitabine in Patients with Solid Tumors.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Checkpoint Kinase 1; Deoxycytidine; Fatigue; Female; Gemcitabine; Half-Life; Humans; Male; Middle Aged; Neoplasms; Neutropenia; Phenylurea Compounds; Pyrazines; Thrombocytopenia; Young Adult | 2016 |
A phase I study of bortezomib, etoposide and carboplatin in patients with advanced solid tumors refractory to standard therapy.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Boronic Acids; Bortezomib; Carboplatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Etoposide; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Nausea; Neoplasms; Neutropenia; Pyrazines; Thrombocytopenia | 2009 |
Phase I trial of fludarabine, bortezomib and rituximab for relapsed and refractory indolent and mantle cell non-Hodgkin lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Humans; Lymphoma, Mantle-Cell; Male; Middle Aged; Nervous System Diseases; Neutropenia; Opportunistic Infections; Pyrazines; Rituximab; Thrombocytopenia; Treatment Outcome; Vidarabine | 2009 |
A randomized phase II study of bortezomib and pemetrexed, in combination or alone, in patients with previously treated advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Therapy, Combination; Dyspnea; Female; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Pemetrexed; Pyrazines; Survival Analysis; Thrombocytopenia | 2010 |
A dose-finding and pharmacodynamic study of bortezomib in combination with weekly paclitaxel in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; bcl-2-Associated X Protein; Boronic Acids; Bortezomib; Cytokines; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasms; Neutropenia; Paclitaxel; Proliferating Cell Nuclear Antigen; Proteasome Inhibitors; Pyrazines; Treatment Outcome | 2010 |
Phase I trial of bortezomib and concurrent external beam radiation in patients with advanced solid malignancies.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Colorado; Combined Modality Therapy; Diarrhea; Dose Fractionation, Radiation; Dose-Response Relationship, Drug; Drug Administration Schedule; Fatigue; Female; Humans; Infusions, Intravenous; Lymphopenia; Male; Maximum Tolerated Dose; Middle Aged; Nausea; Neoplasms; Neutropenia; Palliative Care; Pyrazines; Radiography | 2010 |
Erythroid response and decrease of WT1 expression after proteasome inhibition by bortezomib in myelodysplastic syndromes.
Topics: Adult; Aged; Aged, 80 and over; Boronic Acids; Bortezomib; Diarrhea; Drug Administration Schedule; Erythroid Cells; Female; Fever; Gene Expression; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Neutropenia; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Thrombocytopenia; Treatment Outcome; WT1 Proteins | 2011 |
Carfilzomib: a novel second-generation proteasome inhibitor.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Hematologic Neoplasms; Humans; Multiple Myeloma; Neutropenia; Oligopeptides; Proteasome Inhibitors; Protein Binding; Pyrazines; Thrombocytopenia | 2011 |
Predictive factors for successful salvage high-dose therapy in patients with multiple myeloma relapsing after autologous blood stem cell transplantation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Busulfan; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Kaplan-Meier Estimate; Male; Melphalan; Middle Aged; Multiple Myeloma; Multivariate Analysis; Neutropenia; Peripheral Blood Stem Cell Transplantation; Prognosis; Pyrazines; Recurrence; Retrospective Studies; Salvage Therapy; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome | 2011 |
Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Agents; Area Under Curve; Boronic Acids; Bortezomib; Diarrhea; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Indoles; Lenalidomide; Male; Metabolic Clearance Rate; Middle Aged; Multiple Myeloma; Nausea; Neutropenia; Panobinostat; Pyrazines; Recurrence; Remission Induction; Thalidomide; Thrombocytopenia; Treatment Outcome | 2012 |
High-dose melphalan with bortezomib as conditioning regimen for autologous stem cell transplant in patients with newly diagnosed multiple myeloma who exhibited at least very good partial response to bortezomib-based induction therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bipolar Disorder; Boronic Acids; Bortezomib; Combined Modality Therapy; Dose-Response Relationship, Drug; Female; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Male; Melphalan; Middle Aged; Multiple Myeloma; Nausea; Neutropenia; Pyrazines; Remission Induction; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome | 2012 |
Bortezomib may be safely combined with Y-90-ibritumomab tiuxetan in patients with relapsed/refractory follicular non-Hodgkin lymphoma: a phase I trial of combined induction therapy and bortezomib consolidation.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Agents; Boronic Acids; Bortezomib; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Induction Chemotherapy; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neutropenia; Pyrazines; Radioimmunotherapy; Recurrence; Treatment Outcome; Yttrium Radioisotopes | 2013 |
Phase I/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Survival; Drug Administration Schedule; Drug Synergism; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Neutropenia; Pyrazines; Severity of Illness Index; Survival Analysis; Treatment Outcome | 2006 |
Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed multiple myeloma.
Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Chi-Square Distribution; Dexamethasone; Disease Progression; Disease-Free Survival; Fatigue; Glucocorticoids; Humans; Multiple Myeloma; Nausea; Neutropenia; Pyrazines; Risk; Thrombocytopenia | 2007 |
The proteasome inhibitor bortezomib in combination with gemcitabine and carboplatin in advanced non-small cell lung cancer: a California Cancer Consortium Phase I study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; California; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Synergism; Drug Therapy, Combination; Gemcitabine; Humans; Lung Neoplasms; Middle Aged; Neoplasm Staging; Neutropenia; Proteasome Inhibitors; Pyrazines; Thrombocytopenia; Treatment Outcome | 2008 |
Bortezomib/docetaxel combination therapy in patients with anthracycline-pretreated advanced/metastatic breast cancer: a phase I/II dose-escalation study.
Topics: Adult; Aged; Alopecia; Anthracyclines; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Belgium; Boronic Acids; Bortezomib; Breast Neoplasms; Breast Neoplasms, Male; Diarrhea; Docetaxel; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Nausea; Neutropenia; Prospective Studies; Pyrazines; Spain; Taxoids; Treatment Outcome; United Kingdom; Vomiting | 2008 |
Safety and efficacy of bortezomib and melphalan combination in patients with relapsed or refractory multiple myeloma: updated results of a phase 1/2 study after longer follow-up.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Neutropenia; Pyrazines; Thrombocytopenia | 2008 |
A phase I trial and pharmacokinetic evaluation of CI-980 in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Agents; Area Under Curve; Biological Availability; Carbamates; Central Nervous System Diseases; Drug Tolerance; Female; Humans; Male; Metabolic Clearance Rate; Middle Aged; Nausea; Neoplasms; Neutropenia; Pyrazines; Pyridines | 1997 |
Phase II study of CI-980 (NSC 635370) in patients with previously treated advanced soft-tissue sarcomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Carbamates; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neutropenia; Pyrazines; Pyridines; Sarcoma; Treatment Outcome | 1998 |
Phase I and pharmacological study of CI-980, a novel synthetic antimicrotubule agent.
Topics: Adult; Aged; Antineoplastic Agents; Carbamates; Central Nervous System Diseases; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Male; Metabolic Clearance Rate; Middle Aged; Neoplasms; Neutropenia; Pyrazines; Pyridines; Thrombocytopenia | 1997 |
Phase I and pharmacokinetic study of the differentiating agent vesnarinone in combination with gemcitabine in patients with advanced cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Differentiation; Deoxycytidine; Dose-Response Relationship, Drug; Drug Synergism; Female; Gemcitabine; Humans; Male; Middle Aged; Nausea; Neoplasms; Neutropenia; Pyrazines; Quinolines; Thrombocytopenia; Vomiting | 2000 |
6 other study(ies) available for pyrazines and Neutropenia
| Article | Year |
|---|---|
Bortezomib inhibits STAT5-dependent degradation of LEF-1, inducing granulocytic differentiation in congenital neutropenia CD34(+) cells.
Topics: Antigens, CD34; Boronic Acids; Bortezomib; Cell Differentiation; Cells, Cultured; Congenital Bone Marrow Failure Syndromes; Granulocytes; HEK293 Cells; Hematopoiesis; Hematopoietic Stem Cells; Humans; Lymphoid Enhancer-Binding Factor 1; Neutropenia; Proteolysis; Pyrazines; STAT5 Transcription Factor | 2014 |
Report of 6 cases of large granular lymphocytic leukemia and plasma cell dyscrasia.
Topics: Aged; Aged, 80 and over; Anemia; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Causality; Cladribine; Combined Modality Therapy; Cyclophosphamide; Disease Progression; Female; Humans; Lenalidomide; Leukemia, Large Granular Lymphocytic; Male; Melphalan; Methotrexate; Middle Aged; Multiple Myeloma; Neutropenia; Paraproteinemias; Peripheral Blood Stem Cell Transplantation; Prednisone; Protease Inhibitors; Pyrazines; Registries; Retrospective Studies; Thalidomide | 2014 |
Lenalidomide (Revlimid), bortezomib (Velcade) and dexamethasone for heavily pretreated relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease Progression; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Muscle Weakness; Neutropenia; Pneumonia; Pyrazines; Recurrence; Retrospective Studies; Thalidomide; Treatment Outcome | 2013 |
Neutropenia occurring during treatment with vesnarinone (OPC-8212).
Topics: Cardiomyopathy, Dilated; Cardiotonic Agents; Clinical Trials as Topic; Europe; Female; Granulocyte Colony-Stimulating Factor; Humans; Incidence; Male; Middle Aged; Neutropenia; Pyrazines; Quinolines; Risk Factors; Time Factors; United States | 1994 |
Inotropic agent vesnarinone inhibits cytokine production and E-selectin expression in human umbilical vein endothelial cells.
Topics: 8-Bromo Cyclic Adenosine Monophosphate; Amrinone; Cardiotonic Agents; Cell Adhesion; Cells, Cultured; Colforsin; Cyclic AMP; Cytokines; Depression, Chemical; E-Selectin; Endothelium, Vascular; Gene Expression Regulation; Heart Failure; Hematopoietic Cell Growth Factors; Humans; Intercellular Adhesion Molecule-1; Interleukin-1; Monocytes; Neutropenia; Pyrazines; Quinolines; Tumor Necrosis Factor-alpha; Umbilical Veins; Vascular Cell Adhesion Molecule-1 | 1995 |
Through the looking glass: a positive inotropic drug and ischemic preconditioning.
Topics: 5'-Nucleotidase; Adenosine; Animals; Cardiotonic Agents; Dogs; Drug Approval; Enzyme Activation; Heart Failure; Humans; Ischemic Preconditioning, Myocardial; Myocardial Infarction; Myocardium; Neutropenia; Protein Kinase C; Pyrazines; Quinolines; Second Messenger Systems | 1997 |